Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ann Oncol. 2010 Feb;21(2):319-24. doi: 10.1093/annonc/mdp323. Epub 2009 Jul 24.

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.

Author information

  • 1US Oncology Research, Inc., Houston, TX, USA. Guru.Sonpavde@USOncology.com

Abstract

BACKGROUND:

Systemic therapy options are limited for metastatic castration-resistant prostate cancer (CRPC) patients who progress following docetaxel (Taxotere). This phase II trial evaluated sunitinib malate in patients with progressing metastatic CRPC following prior docetaxel.

PATIENTS AND METHODS:

Patients with metastatic CRPC progressing following one to two chemotherapy regimens including docetaxel were included. The primary end point was progression-free survival (PFS) per radiographic and clinical evaluations. Oral sunitinib was administered 50 mg/day 4-weeks on followed by 2-weeks off per cycle up to a maximum of eight cycles or until clinical progression or intolerable toxicity.

RESULTS:

Thirty-six patients with a median age of 69.5 years were accrued. The median PFS was 19.4 weeks with a 12-week PFS of 75.8%. Four patients (12.1%) had a > or =50% prostate-specific antigen (PSA) decline and seven (21.2%) had a > or =30% PSA decline. Two of 18 patients (11.1%) with measurable disease demonstrated 30% declines by RECIST and eight (44.4%) displayed some shrinkage. A decline in pain score > or =2 points occurred in 13.6% of 22 assessable patients. Drug discontinuation due to toxic effects occurred in 52.8% of patients.

CONCLUSION:

Sunitinib malate demonstrated promising activity in metastatic CRPC progressing after prior docetaxel.

PMID:
19633050
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk